Back to Results

Pacira Pharmaceuticals Inc (PCRX)

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) is a common stock listing tied to Pacira BioSciences, Inc., a healthcare company focused on non-opioid pain management and regenerative health solutions. The company develops, manufactures, markets, distributes, and sells its products to healthcare practitioners in the United States. Its portfolio includes EXPAREL, a bupivacaine liposome injectable suspension used for postsurgical pain control; ZILRETTA, an extended-release injectable suspension for osteoarthritis-related knee pain; and the iovera system, a handheld cryoanalgesia device designed to interrupt pain signals by applying controlled cold to targeted nerves. Pacira is also advancing PCRX-201, a gene therapy vector platform intended for local delivery of genetic medicines, and it has a development and commercialization agreement related to NOCITA for veterinary use. The company was incorporated in 2006 and is headquartered in Brisbane, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PCRX
$47.74
31.1% Upside
Undervalued
$33.57
-7.8% Downside
Fair
Great
0.0%
99.2x
2.2x
1.9x
1.452 B
1.613 B
22.1%
98.2%
2.8
1,226.4%
Valuation • Fair Value

Pacira Pharmaceuticals Inc (NASDAQ-PCRX) Fair Value by Valuation Model

Review the available estimates for Pacira Pharmaceuticals Inc (NASDAQ-PCRX), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$47.74

Estimated upside of 31.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$60.47

Discounted cash flow valuation reference.

Ben Graham Formula Value

$4.07

Classic Ben Graham valuation formula reference.

EPV Fair Value

$31.84

Earnings power value estimate.

Comps Fair Value

$37.67

Comparable-company valuation reference.

Analyst Price Target

$33.57

Analysts imply downside of 7.8%.

How to read these valuation models

Use the 7 available valuation references for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Pacira Pharmaceuticals Inc (NASDAQ-PCRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

746.2 M

Current operating scale indicator.

Revenue Forecast

754.3 M

Forward revenue estimate.

EBITDA

124 M

Current operating profitability reference.

EBITDA Forecast

183.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Pacira Pharmaceuticals Inc (NASDAQ-PCRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Pacira Pharmaceuticals Inc (NASDAQ-PCRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

9

Relatively strong quality score.

Beneish M-Score

-2.97

No elevated caution signal from this screen.

Altman Z-Score

2.8

Intermediate risk zone.

FCF / Net Income

1,226.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Pacira Pharmaceuticals Inc (NASDAQ-PCRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Pacira Pharmaceuticals Inc (NASDAQ-PCRX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Pacira Pharmaceuticals Inc (NASDAQ-PCRX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Pacira Pharmaceuticals Inc (NASDAQ-PCRX) Stock Forecast & Technical Outlook

Review Pacira Pharmaceuticals Inc (NASDAQ-PCRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Pacira Pharmaceuticals Inc (NASDAQ-PCRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Pacira Pharmaceuticals Inc (NASDAQ-PCRX) has a Hold consensus, with 0 buy, 9 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 9
Sell 0
FAQ • Fast Investor Answers

Pacira Pharmaceuticals Inc (NASDAQ-PCRX) Stock FAQ

Data-supported answers about Pacira Pharmaceuticals Inc (NASDAQ-PCRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$47.74
Estimated upside 31.1%
Valuation Rating
Undervalued
Estimated upside of 31.1%
Analyst Target
$33.57
Implied downside 7.8%
Financial Health
Great
Current financial-health read

The current fair value estimate for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is $47.74. This implies an estimated upside of 31.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 31.1% versus the current market price.

The available analyst price target for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is $33.57. The analyst target implies estimated downside of 7.8%.

The current financial health read for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Pacira Pharmaceuticals Inc (NASDAQ-PCRX).

The current P/E ratio listed for Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is 99.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Pacira Pharmaceuticals Inc is 1.452 B.

The current enterprise value listed for Pacira Pharmaceuticals Inc is 1.613 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Pacira Pharmaceuticals Inc is NASDAQ-PCRX, and the stock is listed on NASDAQ.

Pacira Pharmaceuticals Inc (NASDAQ-PCRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Pacira Pharmaceuticals Inc is 22.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Pacira Pharmaceuticals Inc is 98.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B